Cabotegravir for preventing HIV-1 in adults and young people (TA1106)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 November 2025
Cabotegravir with rilpivirine for treating HIV-1 (TA757)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 January 2022